ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO® https://www.globenewswire.com/news-release/2022/02/03/2378482/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-NDA-Resubmission-for-TLANDO.html PDUFA target action date set for March 28, 2022

Antares Pharma Announces Divestiture of Otrexup® https://www.globenewswire.com/news-release/2021/12/15/2353151/0/en/Antares-Pharma-Announces-Divestiture-of-Otrexup.html ...today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022.  ...

Antares Pharma Granted U.S. Patent #11,185,642 'Injection device with cammed ram assembly' https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6129&f=G&l=50&d=PTXT&p=123&S1=20211130&OS=20211130&RS=20211130

https://finance.yahoo.com/news/lpcn-antares-agreement-nash-fast-131800309.html

Antares Pharma Reports Third Quarter 2021 Financial and Operating Results https://www.globenewswire.com/news-release/2021/11/04/2327256/35385/en/Antares-Pharma-Reports-Third-Quarter-2021-Financial-and-Operating-Results.html Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share

Antares Pharma Enters Into Credit Agreement For Credit Facilities Of Up To $40 Million https://last10k.com/sec-filings/atrs/0001016169-21-000034.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=atrs

Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S. https://finance.yahoo.com/news/antares-pharma-enters-exclusive-license-110000356.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACmcGvCVMgXvJisyH7dENdV43bZ9G9OSnQ1kKolpY7XMcXw_pP1W507Dyb9F7Q1crjWuV7kbV-hAr1VMpRk1YIqYv1GmCx7S1jNC0HOwRHg58A3uV1qMVHt8eWMl_RM62gozApJBgLrzIrSagRGR1HZXr3s1v92xV9vwlDNA9Eo4

Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/09/30/2306251/35385/en/Antares-Pharma-Initiates-Phase-I-Study-For-ATRS-1902-For-Adrenal-Crisis-Rescue.html Pharmacokinetic data results expected in 1Q 2022

Antares Pharma Reports Second Quarter 2021 Financial and Operating Results https://www.globenewswire.com/news-release/2021/08/05/2275394/35385/en/Antares-Pharma-Reports-Second-Quarter-2021-Financial-and-Operating-Results.html Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share ...

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/07/22/2267319/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-IND-Application-for-ATRS-1902-for-Adrenal-Crisis-Rescue.html

Bin hier auch mal drin.

Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction https://finance.yahoo.com/news/antares-pharma-announces-partner-idorsia-123000136.html

Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue https://www.globenewswire.com/news-release/2021/06/22/2251054/35385/en/Antares-Pharma-Announces-Submission-of-IND-Application-for-ATRS-1902-for-Adrenal-Crisis-Rescue.html

https://clinicaltrials.gov/ct2/show/NCT04879589 Phase 1 Study of ATRS-2002 in Healthy Male Adults

Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results https://www.globenewswire.com/news-release/2021/03/02/2185091/0/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-and-Operating-Results.html Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million, including a Net Tax Benefit of $46.3 million ...

Watchliste aufgenommen